4D MOLECULAR THERAPEUTICS Reports FY2023 Q2 Earnings Results as of June 30 2023
August 13, 2023
🌥️Earnings Overview
On August 9, 2023, 4D MOLECULAR THERAPEUTICS ($NASDAQ:FDMT) reported their Q2 FY2023 earnings for the period ending June 30, 2023. Revenue for the quarter was USD 0.2 million, a 50.0% year-over-year increase. Net income for the quarter also grew, coming in at -29.6 million compared to -28.1 million the previous year.
Share Price
On Wednesday, 4D MOLECULAR THERAPEUTICS reported their financial results for the second quarter of FY2023, ending June 30 2023. At the start of the day, 4D MOLECULAR THERAPEUTICS stock opened at $16.8 and closed at $17.0, resulting in a small gain of 0.7% from the prior closing price of $16.9. The company also announced that they plan to use the profits from the quarter in order to continue investing in research and development of their innovative technologies in hopes of creating more effective treatments for diseases. Overall, it was a successful quarter for 4D MOLECULAR THERAPEUTICS and investors are optimistic about the company’s prospects moving forward. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for FDMT. More…
| Total Revenues | Net Income | Net Margin |
| 2.29 | -111.37 | -4873.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for FDMT. More…
| Operations | Investing | Financing |
| -93.2 | 72.01 | 144.02 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for FDMT. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 352.5 | 27.36 | 7.74 |
Key Ratios Snapshot
Some of the financial key ratios for FDMT are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -38.3% | – | -5140.3% |
| FCF Margin | ROE | ROA |
| -4292.2% | -27.0% | -20.8% |
Analysis
At GoodWhale, we believe that it is important to analyze the fundamentals of a company before investing. That is why we have analyzed 4D MOLECULAR THERAPEUTICS using our proprietary Risk Rating system. According to GoodWhale, 4D MOLECULAR THERAPEUTICS is a medium risk investment when taking into account its financial and business aspects. However, GoodWhale has detected two risk warnings in 4D MOLECULAR THERAPEUTICS’ balance sheet and cashflow statement, which investors should take into consideration before committing their capital. To access the full report and find out more about 4D MOLECULAR THERAPEUTICS’ financials, simply register on GoodWhale.com – it’s free and easy to use! More…
Peers
The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.
– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)
Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.
– BioLine Rx Ltd ($NASDAQ:BLRX)
BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.
– Gossamer Bio Inc ($NASDAQ:GOSS)
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.
Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.
Summary
4D Molecular Therapeutics reported its Q2 2023 earnings results on August 9th, showing a total revenue of USD 0.2 million, a 50.0% year-over-year increase. Net income for the quarter came in at USD -29.6 million, an increase from the previous year’s -28.1 million. The company appears to be gaining traction in the industry and has shown positive year-over-year growth in all areas.
Investors should consider 4D Molecular Therapeutics as a potential long-term investment opportunity as its focus on molecular therapeutics could prove to be a lucrative area for growth. With the potential for further growth, 4D Molecular Therapeutics may be an attractive investment opportunity for those looking to diversify their portfolios.
